Mundipharma and Purdue reach a new deal to in-licence from ESTEVE full global rights and development responsibilities for novel first-in-class sigma-1 antagonist (S1A or MR309/E-52862)
CAMBRIDGE, England & BARCELONA–(BUSINESS WIRE)– Mundipharma Medical Company Limited and its independent associated company, Purdue Pharma L.P., today announced that, following completion of Phase II...